In Brief: Dynagen NicErase-SL
Executive Summary
Dynagen NicErase-SL: Clinical development of lobeline sublingual tablet is discontinued after combined results of a 750-subject multicenter Phase III trial did not yield statistically significant results. NicErase continues to be developed by Nastech Pharmaceutical for a nasally administered formulation. Dynagen is in discussions with Lohmann Therapie Systeme over development of transdermal and transbuccal patch formulations of NicErase...